Proton Therapy Market Top Players, Segments & Regional Trends By 2034

Straits Research released its highly anticipated report, “Proton Therapy Market Size & Outlook, 2026-2034.” According to the study, the market size is valued at USD 2.18 billion in 2025 and is projected to expand to USD 4.63 billion by 2034, registering a compound annual growth rate (CAGR) of 8.75%.

Market Dynamics

The growth of the proton therapy market is primarily driven by the rising global prevalence of cancer and the increasing demand for highly precise and minimally invasive radiation treatments. Advancements in imaging, beam delivery, and treatment planning technologies have enhanced the safety and accuracy of proton therapy, making it a preferred option for tumors located near critical organs and for pediatric cases. However, the market faces restraints due to the high installation and maintenance costs of proton therapy facilities, limited availability of specialized infrastructure, and a shortage of trained professionals, which collectively restrict access, particularly in developing regions. Despite these challenges, significant opportunities lie in the expansion of compact and single-room proton systems, growing investments in oncology infrastructure across emerging economies, and ongoing clinical trials exploring new cancer indications, all of which are expected to broaden the clinical and commercial potential of proton therapy worldwide.

Market Highlights

• By Type, the single room systems segment is anticipated to register the fastest CAGR of 9.15% during the forecast period.
• By Application, prostate cancer dominated the market in 2025, with a revenue share of 35.02%.
• By Product, the services segment is anticipated to register the fastest CAGR of 9.75%.
• By Technology, the synchrotron-based segment is expected to witness the fastest growth of 9.35%.
• Based on the Delivery Method, the scanning beam is anticipated to register the fastest CAGR of 10.02%.
• Based on End User, the hospitals segment dominated the market in 2025, with a revenue share of 67.28%.
• Regional Insights: North America dominates the market with a 44.17% share, driven by strong healthcare infrastructure, early adoption of advanced radiation technologies, and a high concentration of specialized cancer treatment centers.